Endocrine, Metabolic, Inflammatory Biomarkers to Identify Highgrade Dysplasia/invasive Carcinoma in Patients with IPMN of the Pancreas

Launched by IRCCS SAN RAFFAELE · Nov 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a type of pancreatic cyst called intraductal papillary mucinous neoplasm (IPMN) to find better ways to identify patients who are at high risk for cancer. The researchers believe that by understanding certain biological and imaging markers, they can more accurately distinguish between IPMNs that are harmless and those that may develop into serious conditions like high-grade dysplasia or invasive cancer. The trial has three main goals: to test existing guidelines for managing IPMN, to find new markers that can indicate cancer risk before surgery, and to confirm these markers in a new group of patients.

To participate in this trial, you need to be at least 18 years old and have been diagnosed with IPMN that has been fully examined by a medical professional. Participants should also have the necessary clinical and imaging information that meets specific international guidelines. If eligible, you can expect to undergo tests to help determine your risk level for cancer, and your results may contribute to improving how doctors diagnose and treat this condition in the future. This trial is currently looking for volunteers, so if you're interested or have questions, be sure to talk to your healthcare provider.

Gender

ALL

Eligibility criteria

• cohort A: inclusion criteria:
• • histologically proven IPMNs with full pathological data (type of IPMNs, grade of dysplasia; for invasive IPMNs: grading, pTNM classification, presence of perineural (microvascular infiltration)
• • availability of clinical and imaging criteria for surgical resections defined by International and European guidelines (worrisome features and high-risk stigmata according to International Guidelines and absolute/relative criteria for surgery according to European guidelines
• • age ≥18 years
• exclusion criteria:
• • - lack of preoperative clinical and radiological data according the two guidelines
• Cohort B and C:
• inclusion criteria:
• • Age \>= 18 years
• • Charlson comorbidity index \<7
• • indication for surgery for suspected IPMN